MHRA advises on anticoagulant dose adjustment in patients with renal impairment

Estimated glomerular filtration rate (eGFR) should not be used to adjust doses of direct-acting oral anticoagulants in patients with renal impairment, the MHRA has advised.

For most drugs and for most adult patients of average build and height, eGFR is an acceptable estimate of renal function.

However, use of eGFR to guide dosing of direct-acting oral anticoagulants is known to increase the risk of bleeding events as a consequence of overestimating renal function. In patients taking these drugs, the MHRA says creatinine clearance should be calculated using the Cockcroft-Gault formula to determine dosage adjustments.

Creatinine clearance should also be used to determine dosage adjustments for:

  • patients taking nephrotoxic drugs (such as vancomycin and amphotericin B)
  • elderly patients (aged 75 years and older)
  • patients at extremes of muscle mass (BMI < 18kg or > 40kg/m²)
  • patients taking medicines that are largely renally excreted and have a narrow therapeutic index (such as digoxin and sotalol)

Prescribers can quickly look up dose adjustments for direct-acting oral anticoagulants in renal impairment using the at-a-glance MIMS guide to NOAC dosages in non-valvular atrial fibrillation.

There are currently four direct-acting oral anticoagulants available in the UK: apixaban, dabigatran, edoxaban, and rivaroxaban.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

First COVID-19 vaccine approved for use in the UK from next week

First COVID-19 vaccine approved for use in the UK from next week

The MHRA has approved the COVID-19 vaccine developed...

SGLT2 inhibitors summarised in new MIMS table

SGLT2 inhibitors summarised in new MIMS table

Prescribers can quickly compare key features and benefits...